What medications are appropriate for a patient with tardive dyskinesia?

Management of Tardive Dyskinesia: Medication Recommendations

For patients with moderate to severe or disabling tardive dyskinesia, treat with a VMAT2 inhibitor (valbenazine or deutetrabenazine) as first-line pharmacotherapy 1.

Primary Management Strategy

The most critical initial step is discontinuing or modifying the causative antipsychotic medication if clinically feasible 2. However, this approach requires careful consideration:

• Continue the current antipsychotic at the same dose ONLY if the patient is in full remission AND any medication change would likely precipitate relapse 2
• Otherwise, attempt to either lower the dose or switch to an atypical antipsychotic with lower D2 affinity, most notably clozapine or quetiapine 2, 3

Critical Caveat

The concern over TD should not outweigh the potential benefits of antipsychotics for patients with serious mental illness like schizophrenia 2. For many patients, discontinuing antipsychotics is not possible due to disease relapse 3.

Pharmacological Treatment Options

First-Line: VMAT2 Inhibitors

Valbenazine and deutetrabenazine are the only FDA-approved medications specifically for TD and have the strongest evidence base 1, 4, 5, 6:

• Both medications are safe and effective in reducing TD symptoms 4, 5
• The 2020 APA guideline provides a Level 1B recommendation (highest quality) for VMAT2 inhibitors in moderate to severe or disabling TD 1
• Long-term studies demonstrate sustained safety and effectiveness 4

Important Safety Considerations:

• Serious adverse events include psychiatric symptoms: depression, worsening of schizophrenia, and suicidal ideation 7
• These risks must be weighed against the disabling nature of untreated TD
• Monitor closely for mood changes and psychiatric decompensation

Dosing Specifics

Valbenazine:

• New formulations include sprinkle capsules 4
• 80 mg dose shows significant symptom reduction (SMD = -0.77) 7

Deutetrabenazine:

• Available as once-daily tablet 4
• Typical dosing: 6 mg twice daily, can be titrated 8
• 36 mg dose showed non-significant reduction in some analyses 7

Alternative Pharmacological Options

When VMAT2 inhibitors are unavailable or not tolerated:

Vitamin E:

• Shows significant symptom reduction (SMD = -1.18) 7
• Generally well-tolerated with mild adverse events comparable to placebo 7
• Consider as adjunctive therapy

Insulin:

• Strongest effect size in network meta-analysis (SMD = -2.16) 7
• Limited by practical administration challenges
• Low-certainty evidence 7

Medications to AVOID

Do NOT use anticholinergics (benztropine, trihexyphenidyl) for TD 9. These are appropriate for acute dystonia and parkinsonism, but not for tardive dyskinesia.

Switching Antipsychotic Strategy

If continuing antipsychotic treatment is necessary:

1. Switch from first-generation to second-generation antipsychotics with lower D2 affinity 3
2. Clozapine is the preferred switch option - demonstrated effectiveness in reducing TD symptoms 8, 3
3. Quetiapine is an alternative with lower D2 affinity 3

Case Example

A 69-year-old woman with severe TD unresponsive to multiple treatments achieved remarkable improvement with the combination of deutetrabenazine 6 mg BID + switching from quetiapine to clozapine + modified electroconvulsive therapy 8.

Monitoring Requirements

Establish baseline and ongoing assessment:

• Use the Abnormal Involuntary Movement Scale (AIMS) 2, 5
• Assess for dyskinesias every 3-6 months once antipsychotic therapy is started 2
• Document baseline abnormal movements before initiating antipsychotics 2

Prevention Remains Paramount

The best strategy against TD is prevention 8, 3:

• Limit antipsychotic prescriptions to specific indications
• Use minimum effective doses
• Minimize duration of therapy
• Obtain adequate informed consent regarding TD risk 2

Common Pitfalls

1. Confusing TD with withdrawal dyskinesia: Withdrawal dyskinesias almost always resolve over time, whereas TD may persist even after discontinuation 2
2. Using anticholinergics for TD: These worsen TD and should be avoided 9
3. Failing to consider clozapine: This atypical antipsychotic has dual benefits - treating the underlying psychiatric condition while potentially reducing TD symptoms 8, 3
4. Delaying VMAT2 inhibitor initiation: These are now first-line for moderate-severe TD with Level 1B evidence 1